Similarly, the addition of BMI1 inhibitor to anti-PD-L1 immunotherapy following pre-chemoradiation treatment resulted in synergistic anti-tumor activity in a lung cancer mouse model [334]. This evidence concerns the gene BMI1 and neoplasm.